LH — Laboratory of America Holdings Share Price
- $16.97bn
- $22.06bn
- $12.16bn
- 87
- 44
- 80
- 81
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 13.26 | ||
PEG Ratio (f) | 0.38 | ||
EPS Growth (f) | 52.94% | ||
Dividend Yield (f) | 1.39% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.13 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | 24.84 | ||
Price to Sales | 1.38 | ||
EV to EBITDA | 17.19 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 5.7% | ||
Return on Equity | 4.36% | ||
Operating Margin | 5.83% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 11,554.8 | 13,978.5 | 13,136.1 | 11,863.9 | 12,161.6 | 12,819.65 | 13,471.83 | 1.42% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | -6.47 | +103.26 | +16.69 | -39.51 | -46.36 | +101.32 | +6.8 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Laboratory Corporation of America Holdings provides comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company serves clients in more than 100 countries.
Directors
- Adam Schechter PRE (56)
- Glenn Eisenberg CFO (60)
- Judith Seltz CHO (58)
- Lance Berberian EVP (58)
- Amy Summy EVP (55)
- Sandra Van Der Vaart EVP (61)
- Brian Caveney EVP (47)
- Paul Kirchgraber EVP (59)
- Mark Schroeder EVP (60)
- Peter Wilkinson SVP (50)
- Peter Neupert LED (65)
- Kerrii Anderson IND (64)
- Jean-Luc Belingard IND (72)
- Jeffrey Davis IND (57)
- D. Gary Gilliland IND (66)
- Garheng Kong IND (45)
- Richelle Parham IND (53)
- Kathryn Wengel IND (55)
- Robert Williams IND (72)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- March 8th, 1994
- Public Since
- April 24th, 1991
- No. of Shareholders
- 1,188
- No. of Employees
- 67,000
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 84,293,628
- Address
- 358 S MAIN ST, BURLINGTON, 27215-5837
- Web
- https://www.labcorp.com
- Phone
- +1 3362291127
- Contact
- Chas Cook
- Auditors
- PricewaterhouseCoopers LLP
Latest News for LH
Upcoming Events for LH
Laboratory Corporation of America Holdings Annual Shareholders Meeting
Laboratory Corporation of America Holdings Annual Shareholders Meeting
Dividend For L1CA34.SA - 0.9138 BRL
Dividend For LH.N - 0.7200 USD
Q2 2024 Laboratory Corporation of America Holdings Earnings Release
Q3 2024 Laboratory Corporation of America Holdings Earnings Release
Similar to LH
Agilon Health
New York Stock Exchange
AMERICAN WELL
New York Stock Exchange
AMN Healthcare Services
New York Stock Exchange
Ati Physical Therapy
New York Stock Exchange
Auna SA
New York Stock Exchange
FAQ
As of Today at 01:13 UTC, shares in Laboratory of America Holdings are trading at $201.32. This share price information is delayed by 15 minutes.
Shares in Laboratory of America Holdings last closed at $201.32 and the price had moved by +5.68% over the past 365 days. In terms of relative price strength the Laboratory of America Holdings share price has underperformed the S&P500 Index by -14.75% over the past year.
The overall consensus recommendation for Laboratory of America Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Laboratory of America Holdings dividend yield is 1.43% based on the trailing twelve month period.
Last year, Laboratory of America Holdings paid a total dividend of $2.88, and it currently has a trailing dividend yield of 1.43%.Looking ahead, shares in Laboratory of America Holdings are due to go ex-dividend on 2024-05-28 and the next dividend pay date is 2024-06-12.
Laboratory of America Holdings are due to go ex-dividend on 2024-05-28 and the next dividend pay date is 2024-06-12. The historic dividend yield on Laboratory of America Holdings shares is currently 1.43%.
To buy shares in Laboratory of America Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $201.32, shares in Laboratory of America Holdings had a market capitalisation of $16.97bn.
Here are the trading details for Laboratory of America Holdings:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: LH
Based on an overall assessment of its quality, value and momentum Laboratory of America Holdings is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Laboratory of America Holdings is $241.53. That is 19.97% above the last closing price of $201.32.
Analysts covering Laboratory of America Holdings currently have a consensus Earnings Per Share (EPS) forecast of $14.83 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Laboratory of America Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -18.46%.
As of the last closing price of $201.32, shares in Laboratory of America Holdings were trading -5.38% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Laboratory of America Holdings PE ratio based on its reported earnings over the past 12 months is 13.26. The shares last closed at $201.32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Laboratory of America Holdings' management team is headed by:
- Adam Schechter - PRE
- Glenn Eisenberg - CFO
- Judith Seltz - CHO
- Lance Berberian - EVP
- Amy Summy - EVP
- Sandra Van Der Vaart - EVP
- Brian Caveney - EVP
- Paul Kirchgraber - EVP
- Mark Schroeder - EVP
- Peter Wilkinson - SVP
- Peter Neupert - LED
- Kerrii Anderson - IND
- Jean-Luc Belingard - IND
- Jeffrey Davis - IND
- D. Gary Gilliland - IND
- Garheng Kong - IND
- Richelle Parham - IND
- Kathryn Wengel - IND
- Robert Williams - IND